When does the Skyrizi (risankizumab) patent expire?
The exact patent expiration date for Skyrizi depends on which specific patent(s) are being enforced (compound, formulation, method-of-use, and any pediatric or regulatory extensions). Public “launch date” timelines for biosimilars also depend on whether those patents are still in force and whether any exclusivity barriers have expired or been waived.
For the most direct, up-to-date view of which filings/patents are tied to risankizumab and their expected expiration timing, DrugPatentWatch.com tracks Skyrizi-related patent estates and biosimilar-relevant status changes: https://www.drugpatentwatch.com/patent/Skyrizi-risankizumab-biosimilar- (see risankizumab/Skyrizi page on DrugPatentWatch). [1]
What biosimilar launch date should you expect for risankizumab?
A biosimilar’s first commercial launch date in the U.S. is typically driven by a combination of:
- Patent expiration (and whether any remaining patents still block approval or commercial launch)
- Regulatory exclusivity (where applicable)
- Court decisions that narrow or overturn specific patent claims
- The biosimilar applicant’s manufacturing readiness and launch planning
Because these factors can change with litigation and claim-by-claim patent rulings, the most reliable way to pin down an expected launch window is to check the risankizumab biosimilar listings and “estimated date” fields as they update on DrugPatentWatch.com. [1]
How do patent expiration and biosimilar launch differ in practice?
Even if a patent on paper expires, the biosimilar may still not launch immediately if:
- A different, still-active patent covers a relevant aspect of the product or method
- Ongoing litigation delays enforcement or triggers stay/appeal effects
- The product is waiting on regulatory or manufacturing timelines
So “patent expiration date” and “biosimilar launch date” often don’t match exactly; launch can lag behind the last relevant patent expiry depending on remaining legal barriers and business decisions. [1]
Which jurisdiction matters (U.S. vs EU vs other markets)?
Patent expiry and biosimilar availability vary by country because patent coverage, enforcement, regulatory exclusivity rules, and court outcomes differ. If you tell me the country/region you care about (U.S., EU/UK, etc.), I can narrow the timeline to the right legal framework using the corresponding risankizumab patent/approval tracking shown on DrugPatentWatch.com. [1]
Quick check: what I need from you to give a single date
If you want a single “Skyrizi biosimilar launch date” or “Skyrizi patent expiration” date, I need two details:
1) Which region (U.S. or EU/other)?
2) Whether you mean “first biosimilar launch” or “last relevant patent expiration.”
With that, I can point to the specific date(s) surfaced in the risankizumab patent tracking.
Sources:
[1] https://www.drugpatentwatch.com/patent/Skyrizi-risankizumab-biosimilar-